title: Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  The potential benefit of long-term dual antiplatelet therapy (DAPT) for secondary prevention of atherothrombotic events is unclear. Data from different randomized controlled trials (RCT) using different agents in different subgroups showed inconsistent results.
  
  
  METHODS
  We performed a systematic review and meta-analysis from RCTs that tested different prolonged durations of DAPT for secondary prevention. Long term DAPT arm was defined as those receiving DAPT for more than 12months. Long-term aspirin arm was defined as those receiving either aspirin alone long term or DAPT for less than 12months.
  
  
  RESULTS
  The use of long term DAPT was associated with a significant decrease in composite of death, myocardial infarction (MI) and stroke (6.08% vs. 6.71%; odds ratio OR=0.86 [0.78-0.94]; P=0.001). This reduction of death, MI and stroke was mainly noticed in patients with prior MI or stroke, but not with PAD or multiple risk factors. The reduction was seen with post PCI patients with prasugrel and only in those with prior MI with clopidogrel and ticagrelor. Long-term use of DAPT was associated with significant increase in major bleeding (1.47% vs. 0.88%; OR=1.65 [1.23-2.21]; P=0.001).
  
  
  CONCLUSIONS
  Long-term use of DAPT for secondary prevention is associated with lower risk of death, MI and stroke beneficial especially in patients with prior MI and stroke, but it is associated with increased risk of bleeding. Prolonging DAPT requires careful assessment of the trade-off between ischemic and bleeding complications and should probably be reserved for patients with higher risk for atherothrombotic events.
authors.affiliation: University of Kansas School of Medicine, Kansas City, KS; Section of Cardiology, Christiana Care Health System, Newark, DE. Electronic address: zfanari@gmail.com.
authors.forename: Zaher
authors.initials: Z
authors.lastname: Fanari
authors.affiliation: Section of Cardiology, Christiana Care Health System, Newark, DE.
authors.forename: Amratash
authors.initials: A
authors.lastname: Malodiya
authors.affiliation: Section of Cardiology, Christiana Care Health System, Newark, DE.
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Weiss
authors.affiliation: Section of Cardiology, Christiana Care Health System, Newark, DE.
authors.forename: Sumaya
authors.initials: S
authors.lastname: Hammami
authors.affiliation: Value Institute, Christiana Care Health System, Newark, DE.
authors.forename: Paul
authors.initials: P
authors.lastname: Kolm
authors.affiliation: Section of Cardiology, Christiana Care Health System, Newark, DE; Value Institute, Christiana Care Health System, Newark, DE.
authors.forename: William S
authors.initials: WS
authors.lastname: Weintraub
mesh_terms: D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: Atherothrombotic; Dual antiplatelet therapy; P2Y12 inhibitors; Secondary prevention